Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids

Nikolaj Frost, Jens Kollmeier, Daniel Misch, Claudia Vollbrecht, Christian Grah, Burkhard Matthes, Dennis Pultermann, Elisabeth Olive, Matthias Raspe, Sebastian Ochsenreither, Maximilian von Laffert, Norbert Suttorp, Martin Witzenrath, Christian Grohé